

Allergic rhinitis: not purely a histamine-related disease

Allergic rhinitis is an inflammatory disorder of the nasal mucosa typified by the symptoms of nasal itch, sneeze, anterior nasal secretions, and nasal blockage. These symptoms arise from the interaction between mediators and neural, vascular, and glandular structures within the nose. Nasal itch, sneezes, and rhinorrhoea are predominantly neural in origin, while nasal obstruction is predominantly vascular. Nasal biopsy studies show accumulation of eosinophils within the lamina propria and epithelium and an increase in tissue and cell surface basophils in both seasonal and perennial allergic rhinitis. These cells are in an activated state. Within the epithelium, increased numbers of mast cells, T cells and Langerhans' cells, which induce T-cell activation, are found. The accumulation of these cells can be linked to chemokine and cytokine generation by the epithelial cells themselves. Thus, the tissue cell recruitment is orchestrated by activated mast cells, T cells, and epithelial cells, with the recruited tissue eosinophils also contributing to their persistence at this site through autocrine mechanisms. Mast cells generate an array of mediators including histamine, tryptase, leukotrienes, and prostaglandins. Histamine is also generated by basophils. Eosinophils and basophils contribute to the leukotriene synthesis within the tissue. Histamine nasal insufflation induces nasal itch, sneeze, and rhinorrhoea as well as nasal blockage, thereby reproducing all the symptoms of allergic rhinitis. These effects are primarily mediated by H_1 -receptors, and H_1 -receptor antagonists are a prominent treatment. Antagonism of histamine at these receptors reduces symptoms by about 40–50%, with the greatest effect on the neurally mediated responses. Thus, histamine is a major mediator of allergic rhinitis, but not the sole contributor. Nasal insufflation with leukotrienes, prostaglandins, or kinins is associated with the development of nasal blockage. These mediators act primarily on the nasal vasculature and, in this respect, leukotrienes are potent mediators. Leukotrienes also induce plasma protein exudation, which contributes to the anterior nasal secretions. Studies with combination products have suggested that modifying the effects of both leukotrienes and histamine has complementary effects in relieving nasal symptoms, indicating that both these mediators are relevant to disease expression.

**P. H. Howarth, M. Salagean,
D. Dokic**

Division of Respiratory Cell and Molecular Biology
(MP810), Department of Medical Specialities,
University of Southampton, Southampton, UK

Key words: allergic rhinitis; endothelial cells;
eosinophils; epithelial cells; histamine; Langerhans'
cells; leukotrienes; mast cells; T cells.

P. H. Howarth, BSc(Hons), DM, FRCP
Reader in Medicine and Honorary Consultant Physician
Division of Respiratory Cell and Molecular Biology
(MP810)
Department of Medical Specialities
University of Southampton
Southampton General Hospital
Tremona Road
Southampton
Hants SO16 6YD
UK
Tel. (+ + 44) 023 8079 6889
Fax: (+ + 44) 023 8079 8492

Introduction

Allergic rhinitis is an inflammatory condition of the nasal mucosa that arises on account of an allergen–IgE interaction in sensitized individuals and is characterized typically by the clinical symptoms of nasal itch, bouts of sneezing, nose running, and nasal congestion, giving rise to difficulty in breathing through the nose (1). Nasal biopsies reveal an accumulation of mast cells, eosinophils, and basophils within the airway epithelium in individuals with active disease in addition to eosinophil accumulation within the deeper lamina propria (2–4).

Symptom generation

The accumulated cells are in an activated state, and it is the mediators released by the cells that lead to the

symptom generation through stimulating specific receptors on sensory nerves and blood vessels within the nasal mucosa (5). Stimulation of sensory nerves leads to the sensation of itch, sneezing, and, via reflex stimulation of efferent vagal pathways, glandular secretion and hence anterior rhinorrhoea (Fig. 1). In addition, the local release of neuropeptides, such as substance P (SP) and calcitonin gene-related peptide (CGRP), from non-adrenergic noncholinergic nerves within the nasal mucosa can modify the state of nasal vascular engorgement, either through a direct action on the vessels, promoting vasodilatation, or indirectly by modifying sympathetic ganglionic neurotransmission. The nasal vasculature is under sympathetic tone; the sympathetic neurotransmitter, noradrenaline, promotes vasoconstriction and maintains nasal airway patency. The ganglionic reduction in sympathetic tone by

neuropeptides will thus lead indirectly to nasal congestion. In addition to these neural effects, mediators generated from mast cells, basophils, and eosinophils, such as histamine, tryptase, kinins, prostaglandins (PGs), and leukotrienes (LTs), have direct effects on the nasal vasculature through their interaction with specific receptors.

The nasal vascular anatomy is complex and includes both resistance and capacitance vessels (6). The resistance vessels are predominantly small arteries, arterioles, and arteriovenous anastomoses. These vessels are fed by the anterior and posterior ethmoid arteries, and flow through these vessels is regulated under normal circumstances by sympathetic tone. Arterial blood reaches the venous drainage system, either via superficial capillaries or via arteriovenous anastomoses (Fig. 2).

The superficial capillaries beneath the basement membrane and around the glandular tissue are unusual in being fenestrated, with the fenestrations facing the respiratory epithelium. This fenestration allows unimpeded extravasation of plasma proteins. The fenestrations – holes in the vascular basement membrane that are not covered by endothelial cells – indicate that plasma extravasation is an important intrinsic property of the vessels at this site. Extravasated plasma contains albumin and immunoglobulins, as well as factors involved in the kinin, complement, coagulation, and fibrinolytic systems (7). It is probable that this exudation is essential both for epithelial nutrition and for local immune defence. In contrast to vascular exudation at most other sites, which occurs via gaps in endothelial cells at postcapillary venules and is dependent upon endothelial cell behaviour, the predominant determinant of exudation at this site is arteriolar tone. Arteriolar dilatation promotes exudation, by increasing capillary blood flow and increasing capillary vascular pressure. The balance between arteriovenous anastomotic flow and capillary flow determines the magnitude of exudation. Plasma protein exudation is an important hallmark of the airway inflammation in allergic rhinitis (8).

The arterial blood drains into a venous system composed of a labyrinth of valveless venous sinusoids within the lamina propria that are particularly prominent within the turbinates. The large collapsible venous sinusoids form the capacitance components of the system. Vascular congestion of the venous sinusoid results in engorgement of the turbinates, an increase in nasal airways resistance, and a reduction in nasal airflow. The venous engorgement is under sympathetic regulation and is determined by the tone of the arteriolar, arteriovenous, anastomotic, and muscular venous draining vessels. Nasal blockage and plasma protein exudation are thus reflections of the vascular changes associated with nasal allergy. Many mediators influence this vasculature including histamine, LTs, PGs, and kinins (9).

IgE and rhinitis

The basis for the development of allergic rhinitis is the overexpression of IgE and the interaction of IgE and allergen. A significant relationship has been demonstrated in community epidemiological studies between the level of specific IgE in the serum and the likelihood of expressing clinical rhinitis (10). The nature of the rhinitis depends upon the sensitization, with specific pollen-related IgE against trees, grasses, or weeds giving rise to seasonal-related symptoms, and that against the common indoor allergens, such as those related to house-dust mites, pets, or cockroaches, often leading to perennial disease.

IgE is generated by B cells under the regulation of cytokines generated by T cells. This is determined by key cytokines, such as interleukin (IL)-4 (11) and IL-13 (12), in addition to copromoting cytokines such as IL-6 and specific receptor-ligand interactions that occur during cell-to-cell contact between the two populations of lymphocytes. These signalling interactions involve cognate interactions between B-cell MHC class II and the T-cell receptor/CD3 complex (13), as well as noncognate interactions, involving B-cell-expressed CD40 and its complementary ligand, expressed as activated T cells (14), and between B7-1 and B7-2 and the CD28 receptor (15), also expressed on the T-cell surface. These interactions and B-cell IgE synthesis are primarily considered to take place in draining lymph nodes, with the antigen having been presented to T cells in a modified format by antigen-presenting cells within the nasal mucosa.

At this site, it is the Langerhans' or dendritic cell that appears to be the most capable antigen-presenting cell (16). Immunohistochemical staining of nasal mucosal biopsies has confirmed the presence of these cells and has demonstrated that they increase in number in naturally occurring seasonal allergic rhinitis (17), as well as following repeated laboratory allergen challenge out of season (18). In addition to this, there is now evidence, at least following allergen challenge in the laboratory, that there may be local IgE generation within the nasal mucosa (19). *In situ* hybridization studies have identified increased mRNA expression for the heavy chain for IgE that can be localized to B cells within nasal biopsies taken 24 h after nasal allergen challenge. In the same study, the challenge was associated with increased mRNA expression for IL-4, which was localized predominantly to tissue T cells and to mast cells. Both of these cell populations could thus be linked to this local IgE generation, as, in addition to the described T-cell interactions with B cells, mast cells have been shown to express the CD40 ligand (20), and *in vitro*, in the presence of IL-4, stimulation of CD40 on the B-cell surface can promote IgE synthesis (21). The local generation of IgE provides a ready mechanism for IgE availability to bind to tissue cells. Immunohistochemical




Figure 1. Schematic representation of afferent and efferent neural stimulatory pathways involved in regulation of glandular secretion and nasal vascular volume. $\text{PGF}_{2\alpha}$: prostaglandin $\text{F}_{2\alpha}$; SP: substance P; CGRP: calcitonin-gene-related peptide; NKA: neurokinin A; NPY: neuropeptide Y; ACh: acetylcholine; VIP: vasoactive intestinal polypeptide; NO: nitric oxide.

assessment of IgE localization within nasal mucosal biopsies reveals that, while it is present in several cell populations, most of it is colocalized to tissue mast cells.

Cellular basis of allergic rhinitis

Nasal biopsy studies reveal activation of a range of cell populations, involving both infiltrating cells and resident tissue cells (Fig. 3). The initial response to the allergen involves activation of immune cells. In this

respect, Langerhans' cells, which present antigen to the T cell; the T cell itself; and the mast cell are all important orchestrators of the subsequent cellular response, through their ability to be activated by allergen and to release cytokines that modify the activity of other cell populations. Within the tissue, the epithelial cells and endothelial cells become activated and are involved in the recruitment of cells, such as eosinophils and basophils, from the circulation and their specific accumulation within the epithelium, along with mast




Figure 2. Schematic representation of nasal vasculature, illustrating links between arterial supply and venous drainage and positioning of venous capacitance vessels, whose state of engorgement within the turbinates is determinant of nasal airflow.




Figure 3. Schematic representation of cellular involvement and sequence underlying clinical disease expression in rhinitis.

cells and T cells. The endothelial activation is associated with the upregulation of leukocyte endothelial adhesion molecules, which are involved in the recruitment of the circulating cells. The epithelium can generate a range of products, but specifically the synthesis and release of chemokines, which are involved in the attraction and activation of cells to this site, represent an important process in allergic mucosal inflammation. Our understanding of the sequence of events and the cellular processes has come both from laboratory allergen challenge studies and from studies in naturally occurring disease. It appears that the initial response to allergen represents mast-cell activation due to cross-linkage of IgE, which is bound to the cell surface of mast cells, a process that leads to mast-cell degranulation.

Mast cells

Sequential nasal lavage following nasal allergen challenge in allergic rhinitis identifies the local release of histamine, tryptase, PGD_2 , LTB_4 , and LTC_4 in association with development of nasal pruritus, sneezing, rhinorrhoea, and nasal blockage (22–26). The increase in these mediators is rapid, peaking within 10–15 min of allergen exposure. Although histamine, LTB_4 , and LTC_4 are not specific markers of mast-cell activation, the parallel identification of elevations in tryptase and PGD_2 is indicative of a mast-cell source and is consistent with mast-cell degranulation. In addition to these mediators, elevations in lavage levels of the kinins, kallidin (lysyl-bradykinin), and bradykinin have been reported (24). Kallidin and bradykinin are potent vasoactive peptides, formed as cleavage products from the action of kallikrein on low- and high-molecular-weight kininogens, respectively. The mast-cell protease tryptase possesses kallikrein-like activity and could thus contribute to the kinin generation identified under such circumstances.

Evidence exists for mast-cell activation and changes in mast-cell populations within the nasal mucosa during

naturally occurring allergic rhinitis. Mast cells are constitutive cells of the normal nasal mucosa, but are not normally found superficially within the airway epithelium. Immunohistochemical staining of nasal biopsies with monoclonal antibodies against mast-cell tryptase identifies an increase in mast cells within the airway epithelium in both seasonal and perennial allergic rhinitis, in comparison with biopsy findings in nonatopic, nonrhinitic subjects (3, 4). The activation of these cells is suggested by the identification of elevated levels of the mast-cell mediator tryptase in nasal lavage fluid in both seasonal and perennial allergic disease (27), along with the identification of ultrastructural changes of degranulation on electron microscopic examination of nasal biopsies (28).

In addition to the mediators identified in naturally occurring disease, clear increases in LT levels in nasal lavage fluid also occur (29, 30). These LTs, which are generated from arachidonic acid (Fig. 4), may be




Figure 4. Biochemical pathway for the generation of sulphido-peptide leukotrienes by 5-lipoxygenase pathway in rhinitis.

derived from a variety of cell sources including eosinophils and basophils, in addition to mast cells (31). The release of cytokines from mast cells and from T cells will influence the recruitment of these leukocytes through their activation of endothelial and epithelial cells in addition to any systemic activity on the bone-marrow precursors.

T cells

The T cell represents a significant nonstructural infiltrating cell within the nasal mucosa and an epithelial accumulation in CD4⁺ T cells has been described in rhinitis in both seasonal (32–34) and perennial disease (32, 35). Within perennial (36), but not seasonal (32), disease, increased cell-surface expression on T cells of the activation marker CD25 also occurs. This is associated with an increase in the number of IL-4-, IL-5-, and IL-13-positive cells, indicative of an increase in Th2 cytokine generation, particularly in perennial allergic disease (37, 38). *Ex vivo* studies have identified that the T cells expressing the $\gamma\delta$ T-cell receptor, which specifically increase within the epithelial compartment in perennial allergic rhinitis, are the subpopulation of T cells that generate the Th2 cytokines in allergic as opposed to infective rhinitis (39).

Tissue and luminal cell recruitment: involvement of structural cells

Cytokines generated by mast cells and T cells can initiate the process of leukocyte tissue-cell recruitment. This involves endothelial cell activation, and the adherence, activation, and transendothelial migration of leukocytes, particularly eosinophils, but also basophils and T cells, and their subsequent migration under a chemotactic stimulus toward the epithelium. Activation of the epithelium and chemokine release from these cells can be implicated in this process.

Endothelial activation is an early event in the recruitment of circulating cells (40). The initial aspect of this process is the histamine-related upregulation of the selectin, P-selectin, on the endothelial surface that, along with the cytokine-upregulated E-selectin, induces a rolling margination. This brings the leukocytes into contact with chemokines, such as RANTES (released and normally T-cell expressed and secreted), macrophage inflammatory protein (MIP)-1 α , and IL-8, presented on the endothelial glycocalyx, and activates these cells. Activation results in upregulated expression or functional conformational changes in cell-surface-expressed ligands, such as the β 2 integrins. These integrins recognize specific ligands that allow firm adherence to the endothelial surface. In this respect, the expression of the β 2-integrin, very late antigen 4 (VLA-4), by eosinophils, basophils, and T cells, but not neutrophils, confers some specificity in the recruitment,

as Th2 cytokines, such as IL-4, IL-5, IL-13, and TNF- α , upregulate the leukocyte endothelial cell adhesion molecule VCAM-1 (vascular endothelial cell adhesion molecule 1), which provides firm adherence through its interaction with VLA-4. Endothelial VCAM-1 is overexpressed in rhinitis (41, 42), and its presence can be related to the number of infiltrating eosinophils and T cells (41, 43, 44).

The epithelium forms an interface between the internal and external environment, and these lining cells are activated in rhinitis. There is increased expression of the epithelially expressed intercellular adhesion molecule (ICAM-1) in naturally occurring seasonal rhinitis in both nasal smear and nasal biopsy samples (45, 46). Cultured human airways epithelial cells have been shown to synthesize granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-6, IL-8, and RANTES (47, 48), and the presence of enhanced IL-6, tumour necrosis factor (TNF)- α , IL-8, GM-CSF, and RANTES immunoreactivity has been demonstrated within the airway epithelium in nasal biopsies taken from individuals with perennial allergic rhinitis (49, 50). This activation is also indirectly reflected by the identification of elevated levels of nitric oxide (NO) in nasal luminal air in seasonal and perennial allergic rhinitis (51, 52). NO is generated by nitric oxide synthase (NOS) from the semi-essential amino acid L-arginine, and we and others have found evidence of increased epithelial expression of the inducible form of NOS (iNOS) in allergic airways disease (53). The increased generation of chemokines by the nasal airway epithelium can account for the cell recruitment to this site and to the nasal airway lumen (Fig. 5).

RANTES is expressed by epithelial cells and its generation is increased in atopic rhinitis (54). This chemokine has been implicated in mast-cell, basophil, eosinophil, and T-cell recruitment (55, 56); indeed, this has been confirmed *in vivo*, as nasal challenge with RANTES induces the tissue accumulation of basophils, eosinophils, and T cells (57). Another C-C (with two adjacent cysteine residues) chemokine, eotaxin, is also released by epithelial cells and is probably a key eosinophilic chemokine (58). Eotaxin mRNA is upregulated in the nasal tissue of patients with acute allergic rhinitis (59), and nasal challenge with eotaxin has been found to induce nasal eosinophilic inflammation. Another chemokine, monocyte chemotactic protein (MCP-1), also from the same subclass, may be generated from macrophages and is present within the nasal mucosa (60). It is also overexpressed in seasonal allergic rhinitis (61). This chemokine can activate monocytes and basophils, and is also implicated in eosinophil, T-cell, and monocyte cell influx and accumulation (62). The survival of cells at this site, particularly eosinophils and mast cells, is promoted by the respective epithelial generation of GM-CSF and stem-cell factor (SCF). Cultured nasal epithelial cells have been shown to




Figure 5. Epithelial chemokine generation and its relevance to nasal eosinophil accumulation. Interleukin-8 secretion IgA (IL-8sIgA) complex and RANTES, eotaxin, eotaxin 2, and monocyte chemoattractant protein 4 (MCP-4) are all eosinophil chemoattractants. C-C: chemokines of C-C class; IL: interleukin.

generate SCF *in vitro*, and elevated levels of SCF have been found to be present in nasal lavage fluid in seasonal allergic rhinitis (63). The SCF levels correlated with nasal lavage mast-cell chemotactic activity. In support of this, a further study reported that SCF mRNA expression correlated with both mast-cell numbers and histamine content within the nasal mucosa (64).

TNF- α is an important cytokine regulating epithelial cell activation and is generated by mast cells and T cells. In addition, it is now apparent that allergens, which in themselves are also proteolytic enzymes, can directly activate epithelial cells independently of IgE (65) and lead to cytokine release (66). This process is enhanced by the local generation of the proteases, tryptase and chymase, released in association with mast-cell activation (65) and by the corelease of IL-4 and IL-13 from these cells, as these Th2 cytokines have recently been shown to upregulate epithelial cell activation (67).

The upregulated events involved in allergic airways inflammation are regulated by transcription factors. A number of different transcription factors are involved, but nuclear factor kappa B (NF κ B) appears to be critical. It potentially regulates many products of relevance (68) and is pertinent to the regulation of the endothelial expression of adhesion molecules, such as E-selectin, ICAM-1, and VCAM-1; of chemokines, such as RANTES, eotaxin, MCP-1, TNF- α , and GM-CSF; and of enzymes, such as iNOS, which is involved in NO generation, and 5-lipoxygenase, which is involved in LT synthesis. NF κ B probably functions in tandem with other transcription factors, such as AP-1 and C/EBP, which also control similar genes (69).

Infiltrating leukocytes

Nasal biopsies taken from the normal nose or from monoallergic pollen-sensitive subjects outside the pollen season reveal no evidence of eosinophilic airway inflammation, and nasal smears reveal very few if any basophils in these circumstances. The appearance of these cells within the nasal mucosal tissue and within nasal luminal samples is associated with clinical disease expression. Activation of these cells leads to mediator release, and it is probable that they contribute, along with mast-cell-derived mediators, to the severity of symptom expression.

Eosinophils

The presence of eosinophils within nasal samples, whether from nasal biopsies, nasal smears, or nasal lavage samples, is a feature of allergic nasal disease (70). The eosinophilia may be more marked in seasonal than perennial disease. These eosinophils are activated, as reflected by elevated levels of eosinophil cationic protein (ECP) in nasal lavage. Increased levels of ECP are evident in both seasonal and perennial allergic rhinitis in comparison to the normal nose (27). Eosinophils can also generate a range of other mediators, including LTs, cytokines, chemokines, and growth factors. The generation of IL-5 and eotaxin by these cells may serve an autocrine function. The generation of LTs from eosinophils is likely to contribute to plasma protein exudation, mucus hypersecretion, and nasal blockage.

Basophils

Circulating basophil and eosinophil progenitors are evident in peripheral blood in association with allergic rhinitis (71). These cells are derived from CD34+ progenitor cells within the bone marrow (72). Until recently, the lack of a good monoclonal antibody specific for basophils has hampered assessment of tissue accumulation of basophils, and their identification has largely depended upon ultrastructural evaluation of cells in nasal smear or lavage by transmission electronmicroscopy. There have been reports of basophils increasing within smear samples in active rhinitis (73, 74). Using a recently developed monoclonal antibody designated BB1 (Dr A. Walls, University of Southampton, UK), we have been able to immunostain nasal biopsy sections from normal nonrhinitic subjects and from those with seasonal and perennial allergic rhinitis. The number of basophils within tissue samples is small (median 4–5 cells/mm²) in rhinitis in comparison to mast-cell numbers (median 30–40 cells/mm²), but is significantly increased in both seasonal and perennial disease in comparison to the normal nose (median <1 cell/mm²).

Basophils generate histamine and LTs on activation and are thus another potential cell contributor to the mediators of symptom expression in rhinitis. Supportive of this is the report that nasal smear basophil numbers in rhinitis correlate positively with the severity of the disease (75).

Mediators and symptom expression

Thus, the symptom expression in rhinitis is based on sensory neural stimulation giving rise to nasal itch, sneeze, and rhinorrhoea, while nasal blockage is vascular in origin and is determined predominantly by the direct action of mediators on the nasal blood vessels. A range of mediators has been related to the clinical expression of disease; namely, histamine, kinins, tryptase, PGs (particularly PGD₂), and LTs (particularly LTC₄ and LTD₄). Nasal challenge studies have been undertaken to explore the potential effects of these mediators.

Nasal insufflation with histamine produces a full range of nasal symptoms, including nasal blockage (76). The nasal itch, sneeze, and rhinorrhoea are completely abolished by H₁-receptor antagonists, indicative of the involvement of H₁-receptor stimulation. The nasal blockage is, however, only partially modified by H₁-antagonism. H₂-receptor antagonists can also modify the obstructive response; their effects with H₁-antihistamines are not additive, indicating that their protective effects are sequential in the same process (77). Thus, histamine-induced nasal blockage is incompletely modified by H₁- or H₂-receptor blockade, suggesting that histamine-mediated stimulation

of H₃-receptors may also contribute (78). Nasal blockage is also induced by nasal insufflation with kinins, PGD₂, and LTC₄ and LTD₄. Thus, these mediators will also contribute to allergic disease. Nasal challenge with kinins induces a painful nasal sensation, different from histamine-induced itch, glandular secretion, and plasma protein extravasation (79). These effects are mediated through the kinin β 2 receptor, as the β 2 agonist kallidin, but not the β 1 agonist [des-arg⁹]-bradykinin, mimics the increase in nasal airways resistance and plasma protein exudation induced by bradykinin (80, 81). The effects of PGD₂, LTC₄, and LTD₄ are more limited, their predominant action being to induce nasal blockage. The LTs are also potent mediators of vascular permeability and induce plasma protein exudation (31). The effects of PGD₂ are mediated through a specific vascular receptor termed the DP receptor, as opposed to the common thromboxane (TP) receptor, through which PGD₂ exerts bronchoconstrictor responses within the lower airways (82, 83). The cyst LT₁ receptor is most likely to be the vascular receptor responsible for the nasal effects of LTs.

Conclusions

Allergic rhinitis is an inflammatory nasal disorder in which a range of cells and mediators contribute, in a coordinated complex network that underlies clinical disease expression. Drug therapy is currently directed toward receptor antagonism of mediators, functional antagonism of end-organ responses, and inhibition of cell accumulation and/or activation. Histamine is a major contributor and, as such, receptor antagonists of the H₁-receptors have played a prominent role in management guidelines. Histamine is not, however, the only player, and this strategy will be only partially successful as sole therapy. Inhibition of other mediators is likely to confer additional benefit, and combination therapy with cyst LT₁-receptor antagonists and H₁-receptor antagonists has been tried. Alternatively, the development of drugs that have a broader profile of mediator antagonism/synthesis inhibition would similarly be expected to have a greater effect in improving symptoms. This has been sought with "antiallergic" antihistamines, drugs that block H₁-receptors and also either modify LT production or inhibit cell recruitment, thus decreasing the availability of activated eosinophils or basophils for the "mediator pool".

Acknowledgment

I thank Carol Martin for typing the manuscript.

References

1. HOWARTH PH. Disease pathogenic mechanisms in allergy: a rational basis for treatment. *BMJ* 1998;316:757-761.
2. ENERBÄCK L, PIKORN U, OLAFSSON A. Intraepithelial migration of nasal mucosal mast cells in hay fever. Ultrastructural observations. *Int Arch Allergy Appl Immunol* 1986;88:289-297.
3. BRADDDING P, FEATHER IH, WILSON S, BARDIN P, HOLGATE ST, HOWARTH PH. Immunolocalisation of cytokines in the nasal mucosa of normal and perennial rhinitis subjects: the mast cell as a source of IL-4, IL-5 and IL-6 in human allergic inflammation. *J Immunol* 1993;151:3853-3865.
4. BRADDDING P, FEATHER IH, WILSON S, HOLGATE ST, HOWARTH PH. Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. *Am J Respir Crit Care Med* 1995;151:1900-1906.
5. HOWARTH PH. Seasonal and perennial allergic rhinitis. In: KAY AB, editor. *Allergy and allergic diseases*. Oxford: Blackwell Scientific, 1997:1311-1326.
6. WIDDICOMBE J. Microvascular anatomy of the nose. *Allergy* 1997;52:7-11.
7. ECCLES R. Plasma exudation in rhinitis. *Clin Exp Allergy* 1992;22:319-320.
8. PERSSON CGA, ERIEFÄLT JS, GRIEF L. Plasma-derived proteins in airway defence, disease and repair of epithelial injury. *Eur Respir J* 1998;11:958-970.
9. HOWARTH PH. Mediators of nasal blockage in allergic rhinitis. *Allergy* 1997;52:12-18.
10. BURROWS B, MARTINEZ FD, HALONEN M, BARBEE RA, CLINE MG. Association of asthma with serum IgE levels and skin test reactivity to allergens. *N Engl J Med* 1989;320:271-277.
11. PENE J, ROUSSET F, BRIERE F, et al. IgE production by normal human lymphocytes is induced by interleukin-4 and suppressed by interferon γ and prostaglandin E_2 . *Proc Natl Acad Sci U S A* 1988;85:6880.
12. PUNNONEN J, AYERSA G, COCKS BG, et al. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. *Proc Natl Acad Sci U S A* 1993;90:3730.
13. VERCELLI D, JABARA HH, ARAI K, GEHA RS. Induction of human IgE synthesis requires IL-4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class II antigens. *J Exp Med* 1989;169:1295-1307.
14. SPRIGGS MK, ARMITAGE RJ, STROCKBINE L, et al. Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E synthesis. *J Exp Med* 1992;176:1543.
15. JUNE CH, BLUESTONE JA, NADLER LM, THOMPSON CB. The B7 and CD28 and receptor families. *Immunol Today* 1994;15:321.
16. KAPSONBERG ML, HILKENS CM, WIERENGA EA, KALINSKI P. The paradigm of type I and type II antigen-presenting cells. Implications for atopic allergy. *Clin Exp Allergy* 1999;2:23-26.
17. FOKKENS WJ, VROOM T, RIJNTES E, MULDER P. Fluctuation of the number of CD1a (T6)-positive dendritic cells, in the nasal mucosa of patients with isolated grass pollen allergy before, during and after the grass pollen season. *J Allergy Clin Immunol* 1989;84:39-43.
18. HOLM AF, FOKKENS WJ, GODTHELP T, MULDER PG, VROOM TM, RIJNTES E. Effect of 3 months steroid therapy on nasal T cells and Langerhans cells in patients suffering from allergic rhinitis. *Allergy* 1995;50:204-209.
19. DURHAM SR, GOULD HJ, THIENES CP. Expression of epsilon germ-line transcripts and mRNA for the epsilon heavy chain of IgE in nasal B cells and the effects of topical corticosteroids. *Eur J Immunol* 1997;27:2899-2906.
20. GAUCHET JF, HENCHOZ S, MAZZEL G, et al. Induction of human IgE synthesis in B cells by mast cells and basophils. *Nature* 1993;365:340-343.
21. PAWANKAR R, OKUDA M, YSSEL H, OKAMURA K, RA C. Nasal mast cells in perennial allergic rhinitis exhibit increased expression of the Fc epsilon R1, CD40L, IL-4 and IL-13, and can induce IgE synthesis in B cells. *J Clin Invest* 1997;99:1492-1499.
22. CASTELLS M, SCHWARTZ LB. Tryptase levels in nasal-lavage fluid as an indicator of the immediate allergic response. *J Allergy Clin Immunol* 1988;82:348-355.
23. PROUD D, BAILEY GS, NACLERIO RN, et al. Tryptase and histamine as markers to evaluate mast-cell activation during the responses to nasal challenge with allergen, cold, dry air, and hyperosmolar solutions. *J Allergy Clin Immunol* 1992;89:1098-1110.
24. CRETICOS PS, PETERS SP, ADKINSON NF Jr, et al. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. *N Engl J Med* 1984;310:1626-1630.
25. SHAW RJ, FITZHARRIS P, CROMWELL O, WARDLAW AJ, KAY AB. Allergen-induced release of sulphidopeptide leukotrienes (SRS-A) and LTB₄ in allergic rhinitis. *Allergy* 1985;40:1-6.
26. FREELAND HS, PIKORN U, SCHLEIMER RP, et al. Leukotriene B₄ as a mediator of early and late reactions to antigen in humans. The effect of systemic glucocorticoid treatments *in vivo*. *J Allergy Immunol* 1989;83:634-642.
27. WILSON SJ, LAU L, HOWARTH PH. Inflammatory mediators in naturally occurring rhinitis. *Clin Exp Allergy* 1998;28:220-227.
28. TROTTER CM, ORR TSC. A fine structure of some cellular components in allergic reaction. I. Degranulation of human mast cells in allergic asthma and perennial rhinitis. *Clin Exp Allergy* 1973;3:411-425.
29. MIADONNA A, TEDESCHI A, LEGGIEN E. Behaviour and clinical relevance of histamine and leukotrienes C₄ and B₄ in grass-pollen induced rhinitis. *Am Rev Respir Dis* 1987;136:357-362.
30. KNONI J, CAMPBELL A, ENANDER I, PETERSON CG, MICHEL FB, BOUSQUET J. Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis. *J Allergy Clin Immunol* 1992;90:880-889.
31. HOWARTH PH. The role of leukotrienes in rhinitis. In: ROGER IW, BOTTING J, DAHLEN S-E, editors. *Leukotrienes: new concepts and targets for therapy*. London: Kluwer Academic, 1998:125-137.
32. CALDERON MA, LOZEWICZ S, PRIOR A, JORDAN S, TRIGG CJ, DAVIES RJ. Lymphocyte infiltration and thickness of the nasal mucus membrane in perennial and seasonal allergic rhinitis. *J Allergy Clin Immunol* 1994;93:635-643.
33. SAITO H, ASAKURA K, KATAURA A. Studies on the properties of infiltrating T-lymphocytes and ICAM-1 expression in allergic nasal mucosa. *Acta Otolaryngol (Stockh)* 1994;114:315-323.
34. KARLSSON MG, DAVIDSSON A, HELLQUIST HB. Increase in CD4+ and CD45RO+ memory T-cells in the nasal mucosal of allergic patients. *APMIS* 1994;102:753-758.
35. PAWANKAR RU, OKUDA M, OKUBO K, RA C. Lymphocyte subsets of the nasal mucosa in perennial allergic rhinitis. *Am J Respir Crit Care Med* 1995;152:2049-2068.
36. DURHAM SR, YING S, VARNEY VA, et al. Cytokine messenger RNA expression of IL-3, IL-4, IL-5 and granulocyte/macrophage colony-stimulating factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. *J Immunol* 1992;148:2390-2394.
37. PAWANKAR RU, OKUDA M, HASEGAWA S. Interleukin 13 expression in the nasal mucosa of perennial allergic rhinitis. *Am J Respir Crit Care Med* 1995;152:1059-1062.

38. VARGA EM, JACOBSON MR, TILL SJ, et al. Cellular infiltration and cytokine mRNA expression in perennial allergic rhinitis. *Allergy* 1999;54:338-345.
39. PAWANKAR RU, OKUDA M, SUZUKI K, OKUMURA K, RA C. Phenotypic and molecular characteristics of nasal mucosal gamma delta T cells in allergic and infectious rhinitis. *Am J Respir Crit Care Med* 1996;153:1655-1665.
40. MONTEFORT S, HOLGATE ST, HOWARTH PH. Leucocyte-endothelial adhesion molecules and their role in bronchial asthma and allergic rhinitis. *Eur Respir J* 1993;6:1044-1054.
41. MONTEFORT S, FEATHER IH, WILSON SJ, et al. The expression of leucocyte-endothelial molecules in increases in perennial allergic rhinitis. *Am J Respir Cell Mol Biol* 1992;7:393-398.
42. KARLSSON MG, HELLQVIST HB. Endothelial adhesion molecules for nasal-homing T-cells in allergy. *Virchows Arch* 1996;429:449-454.
43. JAHNSEN FL, HARALDSEN G, AANESSEN JP, HAYE R, BRANDTZAEG P. Eosinophil infiltration is related to increased expression of vascular cell adhesion molecule-1 in nasal polyps. *Am J Respir Cell Mol Biol* 1995;12:624-632.
44. TERADA N, SAGARA H, YAGITA H, et al. The effect of anti-VLA-4 monoclonal antibody on eosinophil accumulation and leukotriene production in nasal mucosa. *Acta Otolaryngol* 1996;116:883-887.
45. CIPRANDI G, PRONZATO C, RICCA V, BAGNASCO M, CANONICA GW. Evidence of intercellular adhesion molecule-1 expression on nasal epithelial cells in acute rhinoconjunctivitis raised by pollen exposure. *J Allergy Clin Immunol* 1994;94:738-746.
46. DEVALIA JL, CALDERON M, SAPSFORD RJ, MCAULAY AE, D'ARDENNE AJ, DAVIES RJ. Cell adhesion molecules expressed by human nasal epithelial cells. *Clin Exp Allergy* 1992;22:120.
47. CROMWELL O, HAMID Q, CORRIGAN CJ, et al. Expression and generation of interleukin-8, IL-6 and granulocyte-macrophage colony-stimulating factor by bronchial epithelial cells and enhancement by IL-1 α and tumour necrosis factor- α . *Immunology* 1992;77:330-337.
48. WANG JH, DEVALIA JL, XIA C, SAPSFORD RJ, DAVIES RJ. Expression of RANTES in human bronchial epithelial cells *in vitro* and *in vivo* and the effects of corticosteroids. *Am J Respir Cell Mol Biol* 1996;14:27-35.
49. SAITO H, WILSON S, HOWARTH P. Epithelial and endothelial cell activation and NF κ B expression in allergic rhinitis. *Am J Respir Crit Care Med* 1997;155:A980.
50. SAITO H, WILSON S, HOWARTH P. RANTES expression in the nasal mucosa: relationship to allergic rhinitis and NF κ B expression. *Eur Respir J* 2000 (in press).
51. MARTIN U, BRYDEN K, DEVOY M, HOWARTH PH. Increased levels of exhaled nitric oxide during nasal and oral breathing in subjects with seasonal rhinitis. *J Allergy Clin Immunol* 1996;97:768-772.
52. HOWARTH PH. Mucosal inflammation and rhinitis. In: NACLERIO RM, DURHAM SR, MYGIND N, editors. *Rhinitis. Mechanisms and management*. New York: Marcel Dekker, 1999:109-134.
53. KAWAMOTO H, TAKENO S, YAJIN K. Increased expression of inducible nitric oxide synthase in nasal epithelial cells in patients with allergic rhinitis. *Laryngoscope* 1999;109:2015-2020.
54. CALDERON MA, DEVALIA JL, PRIOR AJ, SAPSFORD RJ, DAVIES RJ. A comparison of cytokine release from epithelial cells cultured from nasal biopsy specimens of atopic patients with and without rhinitis and nonatopic subjects without rhinitis. *J Allergy Clin Immunol* 1997;99:65-76.
55. VON COILLIE E, VON DAMME J, OPDENAKKER G. The MCP/eotaxin subfamily of C-C chemokines. *Cytokine Growth Factor Rev* 1999;10:81-86.
56. MATTOLI S, ACKERMAN V, VI HORI E, MARINI M. Mast cell chemotactic activity of RANTES. *Biochem Biophys Res Commun* 1995;209:316-321.
57. KUNA P, ALAM R, RUTA U, GORSKI P. RANTES induces nasal mucosal inflammation rich in eosinophils, basophils and lymphocytes *in vivo*. *Am J Respir Crit Care Med* 1998;157:873-879.
58. GUTIERREZ-RAMOS JC, LLOYD C, GONZALO JA. Eotaxin from an eosinophilic chemokine to a major regulator of allergic reaction. *Immunol Today* 1999;30:500-504.
59. MINSHALL EM, CAMERON L, LAVIONE F, et al. Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced responses in seasonal allergic rhinitis. *Am J Respir Cell Mol Biol* 1997;17:683-690.
60. FUJIKURA T, OTSUKA H. Monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 mediated histamine release from human nasal mucosa. *Arch Otolaryngol Head Neck Surgery* 1998;124:1331-1335.
61. KUNA P, LAZAROVIC M, KAPLAN MAP. Chemokines in seasonal allergic rhinitis. *J Allergy Clin Immunol* 1996;77:104-112.
62. CHRISTODOULOUPOULOS P, WRIGHT E, FRENKIEL S, LUSTER A, HAMID Q. Monocyte chemotactic proteins in allergen induced inflammation in the nasal mucosa: effects of topical corticosteroids. *J Allergy Clin Immunol* 1999;103:1036-1044.
63. NILSSON G, HUERTSON M, ANDERSSON M, et al. Demonstration of mast-cell chemotactic activity in nasal lavage fluid: characterization of one chemotaxin as c-kit ligand, stem cell factor. *Allergy* 1998;53:874-879.
64. OTSUKA H, KUSUMI T, KANAI S, KOYAMA M, KUNO Y, TAKIZAWA R. Stem cell factor mRNA expression and production in human nasal epithelial cells: contribution to the accumulation of mast cells in the nasal epithelium of allergy. *J Allergy Clin Immunol* 1998;102:757-764.
65. THOMPSON PJ. Unique role of allergens and the epithelium in asthma. *Clin Exp Allergy* 1998;5:110-116.
66. KING C, BRENNAN S, THOMPSON PJ, STEWART GA. Dust-mite proteolytic allergens induce cytokine release from cultured airway epithelium. *J Immunol* 1998;161:3645-3651.
67. KATO M, LIU Q, HATTORI T, NAKASHIWA I. Evidence of potential regulation by interleukin-4 of the soluble intercellular adhesion molecular 1 level in patients with seasonal allergic rhinitis under provocation by a small amount of natural allergen. *Ann Otol Rhinol Laryngol* 1998;107:232-235.
68. BARNES PJ, KARIN M. Nuclear factor- κ B: a pivotal transcription factor in chronic inflammatory diseases. *N Engl J Med* 1997;336:1066-1071.
69. VAN DER STOLPE A, CALDENHOVEN E, STADE BG, et al. 12-O-tetradecanoyl phorbol-13-acetate and tumour necrosis factor alpha mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of intercellular adhesion molecule-1 promoter. *J Biol Chem* 1994;269:6184-6192.
70. HOWARTH PH, WILSON SJ. Eosinophils and rhinitis. In: BUSSE W, HOLGATE ST, editors. *Asthma and rhinitis*. Oxford: Blackwell Scientific, 2000;1:480-499.
71. OTSUKA H, DOLOVICH J, BEFUS AD, BIENENSTOCK J, DENBURG JA. Peripheral blood basophils, basophil progenitors and nasal metachromatic cells in allergic rhinitis. *Am Rev Respir Dis* 1986;133:757-762.
72. KIRSCHENBAUM AS, KESSLER SW, GOTT JP, METCALFE DD. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. *J Immunol* 1991;146:1410-1415.

Howarth

73. OTSUKA H, DENBURG JA, DOLOVITCH J, et al. Heterogeneity of instachromatic cells in human nose: significance of mucosal mast cells. *J Allergy Clin Immunol* 1985;76:695.
74. OKUDA M, OTSUKA H, KAWABORI S. Studies on nasal surface basophilic cells. *Ann Allergy* 1985;54:69.
75. SCHROEDER JT, KAGEY-SABOTKA A, LICHTENSTEIN LM. The role of the basophil in allergic inflammation. *Allergy* 1995;50:463-472.
76. MYGIND N, SECTER C, KIRKEGAARD J. Role of histamine and antihistamines in the nose. *Eur J Respir Dis* 1993;64 Suppl 128:16-20.
77. WOOD-BAKER R, LAU LCK, HOWARTH PH. Histamine and the nasal vasculature: the influence of H₁ and H₂ histamine receptor antagonism. *Clin Otolaryngol* 1996;21:348-352.
78. ISHIKAWA S, SPERELAKIS N. A novel class (H₃) of histamine receptors on perivascular nerve terminals. *Nature* 1987;327:158-160.
79. RAJAKULASINGAM K, POLOSA R, CHURCH MK, HOLGATE ST, HOWARTH PH. Kinins and rhinitis. *Clin Exp Allergy* 1992;22:734-740.
80. RAJAKULASINGAM K, POLOSA R, HOLGATE ST, HOWARTH PH. Comparative nasal effects of the kinins, bradykinin kallidin and [des-arg⁹]-bradykinin in nonrhinitic and atopic rhinitic subjects. *J Physiol* 1991;437:577-587.
81. RAJAKULASINGAM K, LAU LCK, POLOSA R, CHURCH MK, HOLGATE ST, HOWARTH PH. The temporal relationship between the neural and vascular actions of kallidin within the nose and their comparison with bradykinin and [des-arg⁹]-bradykinin. *Mediators Inflamm* 1993;92:140-142.
82. HARRISON K, ROBINSON C, BREWSTER H, HOWARTH PH. Comparative effects of prostaglandin D₂, 9 α 11 α PGF₂ and histamine on nasal airflow in prostaglandins and related compounds. In: *Prostaglandins and related compounds. 7th International Conference Proceedings* 1990:323.
83. JOHNSTON S, SMITH S, HARRISON J, RITTER W, HOWARTH PH. The effect of BAYu3405, a thromboxane receptor antagonist, on prostaglandin D₂-induced nasal blockage. *J Allergy Clin Immunol* 1993;91:903-909.